From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidity
Total (n = 211) | SVD (n = 53) | |||
---|---|---|---|---|
HR | P-value | HR | P-value | |
Mitroflow valve size 21 | 1.13 | 0.41 | 0.65 | 0.16 |
Sex (man) | 1.19 | 0.27 | 1.13 | 0.72 |
Age (ref: 60–69 years) | 1.00 | |||
70–79 years | 1.07 | 0.78 | 1.21 | 0.55 |
> 80 years | 0.99 | 0.98 | 1.71 | 0.29 |
BSA (> 1.73 m2) | 1.15 | 0.38 | 1.87 | 0.25 |
NYHA (ref: I) | 1.00 | |||
II | 1.20 | 0.48 | 1.18 | 0.73 |
III | 1.40 | 0.18 | 1.29 | 0.55 |
IV | 2.10 | 0.06 | NA | |
EF (< 50%) | 1.12 | 0.50 | 0.80 | 0.51 |
Smoker (ref: no) | 1.00 | |||
Previously | 1.57 | 0.01 | 1.14 | 0.69 |
Active | 1.41 | 0.08 | 1.30 | 0.48 |
Diabetes (yes) | 0.99 | 0.95 | 1.18 | 0.69 |
IHD (yes) | 1.07 | 0.61 | 0.99 | 0.97 |
Hypertension (yes) | 0.96 | 0.79 | 1.10 | 0.73 |